IP Library Granted Patent US 9,587,032
Granted Patent B2
US 9,587,032 · App. 13/939,781 · Granted Mar 7, 2017

IgE antibodies for the inhibition of tumor metastasis

Inventors: Joseph A. Mollick (Palo Alto, CA); Pearline Teo (Buona Vista, SG); Paul J. Utz (Stanford, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C07K16/2887C07K16/3092A61K2039/505C07K2317/52C07K2317/70C07K2317/73
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,587,032
App. No.
13/939,781
Granted
Mar 7, 2017
Kind
B2
Abstract

The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.

Claims (13)

1. An IgE monoclonal antibody that specifically binds an epitope of MUC1 and is capable of modulating immune effector cells to inhibit tumor metastasis having a heavy chain variable region encoded by a nucleic acid comprising CDRs 1-3 of a heavy chain variable region encoded by SEQ ID NO: 1 and a light chain variable region encoded by a nucleic acid comprising CDRs 1-3 of a light chain variable region encoded by SEQ ID NO: 2, optionally humanized.

2. The antibody of claim 1 , which has a constant region that is of human origin.

3. The antibody of claim 1 , which is a chimeric antibody.

4. The antibody of claim 1 , which is a humanized antibody.

5. The antibody of claim 1 , which is 3C6.hIgE.

6. A method for inhibiting metastasis of a solid tumor in a patient, comprising the step of administering to the patient the antibody of claim 1 .

7. The method of claim 6 , wherein the antibody has a constant region that is of human origin.

8. The method of claim 6 , wherein the antibody is a chimeric antibody.

9. The method of claim 6 , wherein the antibody is a humanized antibody.

10. The method of claim 6 , wherein the antibody is 3C6.hIgE.

11. The method of claim 6 , wherein the antibody is administered to the patient prior to the development of metastasis in the patient.

12. The method of claim 6 , wherein the solid tumor is of epithelial origin.

13. The method of claim 6 , wherein the solid tumor is breast cancer, colorectal cancer, ovarian cancer, renal cancer, prostate cancer, bladder cancer, gastrointestinal cancer, pancreatic cancer, or lung cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2014
From: MOLLICK, JOSEPH A.; TEO, PEARLINE; UTZ, PAUL J.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 031971/0353 →
CONFIRMATORY LICENSE Recorded Nov 21, 2013
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031693/0954 →
Continuity (2)
Provisional Application 61834169 · Jun 12, 2013
Related Publication 20140370001A1 · Dec 18, 2014